These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 27150391)

  • 1. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
    Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr-/- Mice.
    Park JG; Xu X; Cho S; Lee AH
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1772-81. PubMed ID: 27417587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y; Liu XQ; Rall SC; Mahley RW
    J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
    Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
    Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
    Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice.
    Zsigmond E; Kobayashi K; Tzung KW; Li L; Fuke Y; Chan L
    Hum Gene Ther; 1997 Nov; 8(16):1921-33. PubMed ID: 9382958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
    Sun H; Samarghandi A; Zhang N; Yao Z; Xiong M; Teng BB
    Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1585-95. PubMed ID: 22580899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
    Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
    Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice.
    Wang Y; Tang W; Yang P; Shin H; Li Q
    Biochem Biophys Res Commun; 2018 May; 499(3):626-633. PubMed ID: 29601818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.